All In Biotech

Drug Trial Radar · NCT06226766

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Jan 18, 2024

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced unresectable or metastatic solid malignant tumors that are expected to be HER2 expression (IHC ≥ 1+).

Conditions

  • Advanced Solid Tumor

Interventions

  • JSKN033 InjectionDrug

    JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), assessed by CTCAE V5.0Time frame: Postdose of last participant up to 1 year
  2. RP2D( recommend Phase II dose)Time frame: Postdose of last participant up to 1 year
  3. DLTs (Dose-limiting toxicities)Time frame: Baseline up to 21 days after the first dose
  4. Objective Response Rate (ORR) Following Treatment With JSKN033 in Participants With Advanced Solid Malignant TumorsTime frame: From 6 weeks postdose of last participant up to 1 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.